Revolution Medicines to Present Preclinical Data at the Upcoming American Association for Cancer Research Annual Meeting 2023

April 6, 2023

REDWOOD CITY, Calif., April 06, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced the company and its collaborators will present preclinical data at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2023 being held April 14-19, 2023, in Orlando, Florida.

Details of the planned presentations are listed below:

Revolution Medicines Oral Presentations:

Title:	Discovery of RMC-6291, a tri-complex KRAS^{G12C}(ON) inhibitor
Presenter:	Jim Cregg, Ph.D.
Abstract Number:	ND07
Session:	New Drugs on the Horizon: Part 2
Date/Time:	3:45 – 4:00 p.m. Eastern on April 16, 2023

Title:	RMC-9805, a first-in-class, mutant-selective, covalent and orally bioavailable KRAS^{G12D}(ON) inhibitor, promotes cancer-associated neoantigen recognition and synergizes with immunotherapy in preclinical models
Presenter:	Marie Menard, Ph.D.
Abstract Number:	3475
Session:	Immune Checkpoints at Tumor Beds
Date/Time:	3:37 – 3:52 p.m. Eastern on April 17, 2023

Revolution Medicines Poster Presentations:

Title:	RMC-9805, a first-in-class, mutant-selective, covalent and oral KRAS^{G12D}(ON) inhibitor that induces apoptosis and drives tumor regression in preclinical models of KRAS^{G12D} cancers
Presenter:	Lingyan Jiang, Ph.D.
Abstract Number:	526/26
Session:	Novel Antitumor Agents 2
Date/Time:	1:30 – 5:00 p.m. Eastern on April 16, 2023

Title:	RMC-0708 (RM-046), a first-in-class, mutant-selective and oral KRAS^{Q61H}(ON) inhibitor that drives tumor regression in preclinical models and validates KRAS^{Q61H} as a therapeutic target
Presenter:	Yu C. Yang, Ph.D.
Abstract Number:	1598/21
Session:	New Therapeutic Targeted Agents
Date/Time:	9:00 a.m. – 12:30 p.m. Eastern on April 17, 2023

Collaborator Oral Presentation:

Title:	Combining KRAS^{G12C}(ON) inhibition with SHP2 and immune checkpoint blockade to enhance anti-tumor immunity and overcome development of resistance in lung cancer
Abstract Number:	5733
Session:	New Tricks for Known Targets: Novel Approaches to Inhibit Oncogenic Signaling
Presentation Time:	2:37 – 2:52 p.m. Eastern on April 18, 2023

Collaborator Poster Presentations:

Title:	Bi-steric mTORC1-selective inhibitors activate 4EBP1, suppress MYC, restore anti-tumor immunity, and cooperate with immune checkpoint inhibition to elicit tumor regression
Abstract Number:	LB015/7
Session:	Late-Breaking Research: Experimental and Molecular Therapeutics 1
Presentation Time:	1:30 – 5:00 p.m. Eastern on April 16, 2023

Title:	Preclinical evaluation of RM-042, an orally bioavailable inhibitor of GTP-RAS, in models of pancreatic ductal adenocarcinoma
Abstract Number:	1725/22
Session:	Oncogenes and Tumor Suppressor Genes as Targets for Therapy 2
Date/Time:	9:00 a.m. – 12:30 p.m. Eastern on April 17, 2023

Title:	Bi-steric mTORC1 inhibitors are superior to rapamycin and induce apoptotic cell death in tumor models with hyperactivated mTORC1
Abstract Number:	4859/2
Session:	Anticancer Approaches Targeting Signal Transduction Pathways
Presentation Time:	1:30 – 5:00 p.m. Eastern on April 18, 2023

Additional information on the AACR Annual Meeting 2023 is available through the AACR website at: https://www.aacr.org/meeting/aacr-annual-meeting-2023/

About Revolution Medicines, Inc.

Revolution Medicines is a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) Inhibitors designed to suppress diverse oncogenic variants of RAS proteins, and RAS Companion Inhibitors for use in combination treatment strategies. The company's RAS(ON) Inhibitors RMC-6236 (RAS ^{MULTI}) and RMC-6291(KRAS^{G12C}) are currently in clinical development. Additional RAS(ON) Inhibitors in the company's pipeline include RMC-9805 (KRAS ^{G12D}) and RMC-0708 (KRAS^{Q61H}), both of which are currently in IND-enabling development, RMC-8839 (KRAS^{G13C}), and additional compounds targeting other RAS variants. RAS Companion Inhibitors in clinical development include RMC-4630 (SHP2) and RMC-5552 (mTORC1/4EBP1).

Contacts: For Investors & Media: Erin Graves 650-779-0136 egraves@revmed.com